List view / Grid view
21 October 2015 | By Victoria White
Research has found that women whose breast cancer had begun to spread and who tested positive in the αB-crystallin test were three times more likely to have disease that spread to the brain...
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
26 August 2015 | By Victoria White
Alliance Foundation Trials, the Austrian Breast & Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study...
21 August 2015 | By Victoria White
The EMA has validated for review a MAA for Ibrance in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer...
31 July 2015 | By Victoria White
Eisai and Halozyme are to collaborate to evaluate Halaven in combination with PEGPH20 in first line HER2-negative metastatic breast cancer...
31 July 2015 | By Victoria White
The EC has approved the use of Perjeta in combination with Herceptin and chemotherapy for use before surgery in patients with early stage breast cancer...
24 July 2015 | By Victoria White
A study of more than 30,000 women shows that aromatase inhibitors substantially reduce the risk of death in postmenopausal women ER-positive breast cancer...
21 July 2015 | By Victoria White
BioMarin has provided an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib...
9 July 2015 | By Victoria White
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available hormone progesterone added to their treatment...
29 June 2015 | By Victoria White
The CHMP has recommended that the EC approves the use of Perjeta for the neoadjuvant treatment of adult patients with HER2-positive early breast cancer...
1 June 2015 | By Victoria White
Roche has announced new results from the Phase II NeoSphere study that assessed a Perjeta regimen in people with HER2-positive early breast cancer...
1 April 2015 | By Victoria White
Peregrine has announced promising clinical data from a Phase I trial evaluating bavituximab therapy in patients with metastatic breast cancer...
30 September 2014 | By Roche
Roche announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer...
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
